Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC [Phase 2]
Open-label Phase 2 trial comparing Lutetium-177 vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor ve…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]
Phase 2 clinical trial evaluating the combination of FPI-2265 (225Ac-PSMA-I&T) and Olaparib for metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: External Beam and Radioligand Radiotherapy for mCRPC [Phase 2]
Phase 2 clinical trial update describing a study of external beam radiotherapy combined with radioligand radiotherapy for metastatic castrat…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trial evaluates PDS01ADC in combination with docetaxel and abiraterone for metastatic castration-sensitive and metastatic cast…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 clinical trial evaluating adverse events and how ABBV-969 distributes in the body for adults with metastatic castration-resistant pr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial to test Inavolisib for metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]
Phase 2 clinical trial of FPI-2265 (225Ac-PSMA-I&T) for PSMA-positive metastatic castration-resistant prostate cancer; the study is currentl…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]
This is a Phase 1 clinical trial update for AB001, an alpha radioligand therapy, in metastatic castration-resistant prostate cancer; the stu…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial [Phase 2]
The PREDICT trial is a Phase 2 targeted therapy study for metastatic prostate cancer and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer [Phase 4]
A Phase 4 clinical trial is evaluating continuation versus de-escalation of bone-modifying agents in patients with bone metastases from brea…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). [Phase 2]
A Phase 2 trial evaluating targeted alpha therapy with Actinium-225 PSMA-I&T for metastatic castration-resistant prostate cancer, sponsored …
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating ASP5541 in participants with prostate cancer, including metastatic castration-resistant and metastatic h…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan [Phase 2]
A Phase 2 clinical trial in Japan evaluating 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer is sponsored by Novartis and…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating 161Tb-RAD402 for castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]
A first-in-human Phase 1 clinical trial evaluating 225Ac-PSMA-Trillium (BAY 3563254) in patients with advanced metastatic castration-resista…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC [Phase 1]
Phase 1 clinical trial evaluating autologous gamma delta T cells targeting PSCA in metastatic castration-resistant prostate cancer; currentl…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]
Clinical trial update announcing AB-3028, a programmable circuit T cell therapy, for metastatic castration-resistant prostate cancer, with P…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types [Phase 1]
IDEAYA Biosciences is conducting a Phase 1 study of IDE034 in adults with multiple locally advanced or metastatic solid tumors; the trial is…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy [Phase 1]
A Phase 1 clinical trial investigating image-guided biopsies to identify resistance mechanisms in patients with metastatic castration-resist…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This document reports the status of a Phase 1 study of AMG 509 in participants with metastatic castration-resistant prostate cancer, which i…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]
Phase 2 trial evaluating darolutamide for metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors [Phase 1, Phase 2]
This clinical trial update describes ongoing Phase 1/2 studies of the radiopharmaceutical 177Lu-BetaBart. The trial is evaluating its use in…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer [Phase 2]
A Phase 2 trial comparing lutetium-177-PSMA-617 to docetaxel in metastatic castration-resistant, PSMA-positive prostate cancer; the study is…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer [Phase 1]
A Phase 1 clinical trial of Xaluritamig in adults with metastatic castration-resistant prostate cancer is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease [Phase 2]
A Phase 2 clinical trial evaluating intensified 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer with low PSMA exp…